Pregabalin and Orofacial Neuropathic Pain

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Neuropathic PainOrofacial Pain
Interventions
DRUG

pregabalin

Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.

DRUG

placebo

Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.

Trial Locations (2)

M9V 4B8

Dr. P. Watson's office, Etobicoke

M5G1G6

University of Toronto, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Toronto

OTHER